Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

ZHCLF

Rank in Stocks #26924
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Share Price
$0.0004
Last synced: 2026-11-13
Market Cap
$17.30M
Change (1 day)
0.00%
Change (1 year)
-99.20%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Resverlogix Corp. (ZHCLF)
EPS as of July 2026 TTM: $-0.06
According to Resverlogix Corp.'s latest financial reports, its current EPS (TTM) is $-0.06. At the end of 2025 the company had an EPS of $-0.05, an increase over its 2024 EPS of $-0.07.
EPS history for Resverlogix Corp. from 2013 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.06 14.20%
2025 $-0.05 -31.19%
2024 $-0.07 -26.03%
2023 $-0.09 64.35%
2022 $-0.06 11.43%
2021 $-0.05 51,500.00%
2020 0.00 0.00%
2019 0.00 -99.85%
2018 $-0.07 16.82%
2017 $-0.06 -32.57%
2016 $-0.08 -4.05%
2015 $-0.09 -68.00%
2014 $-0.27 22.73%
2013 $-0.22 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 1,458.67%
US
$15.66 -27,525.57%
US
$-7.07 12,281.79%
US
$-5.29 9,164.45%
AU
$12.73 -22,398.07%
BE

Questions about Resverlogix Corp.'s earnings per share (EPS)

What is Resverlogix Corp.'s earnings per share (EPS)?

Resverlogix Corp.'s earnings per share (EPS) over the last twelve months is $-0.06, as of Jul 2026.

What was Resverlogix Corp.'s earnings per share (EPS) in 2025?

In 2025, Resverlogix Corp.'s earnings per share (EPS) was $-0.05, compared with $-0.07 in 2024.

How has Resverlogix Corp.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Resverlogix Corp.'s earnings per share (EPS) was highest in 2020 (0.00) and lowest in 2023 ($-0.09).

How does Resverlogix Corp.'s earnings per share (EPS) compare with similar companies?

Resverlogix Corp.'s earnings per share (EPS) ($-0.06) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.